Determinants of Serum Antipyrine Half-lives in Patients with Liver Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 1973 Jul 1

PMID 4729926

Citations 63

Authors

R A Branch

C M Herbert

A E Read

Affiliations

Soon will be listed here.

Abstract

Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T(1/2)) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T(1/2) was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.

Citing Articles

Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature.

Lenoir C, Rollason V, Desmeules J, Samer C Front Pharmacol. 2021; 12:733935.

PMID: 34867341 PMC: 8637893. DOI: 10.3389/fphar.2021.733935.

Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Fabre D, Bressolle F, Gomeni R, Bouvet O, Dubois A, Raffanel C Clin Pharmacokinet. 1993; 24(4):333-43.

PMID: 8491059 DOI: 10.2165/00003088-199324040-00006.

Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.

Barbhaiya R, Shukla U, Pfeffer M, PITTMAN K, Shrotriya R, Laroudie C Eur J Clin Pharmacol. 1994; 46(1):41-7.

PMID: 7911763 DOI: 10.1007/BF00195914.

Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Abei M, Tanaka E, Tanaka N, Matsuzaki Y, Ikegami T, Ishikawa A J Gastroenterol. 1995; 30(4):478-84.

PMID: 7550858 DOI: 10.1007/BF02347564.

Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Sultatos L, Dvorchik B, Vesell E, SHAND D, Branch R Clin Pharmacokinet. 1980; 5(3):263-73.

PMID: 7389235 DOI: 10.2165/00003088-198005030-00005.

References

Levi A, Sherlock S, Walker D . Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968; 1(7555):1275-9. DOI: 10.1016/s0140-6736(68)92292-7. View

Vesell E, Page J . Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969; 48(12):2202-9. PMC: 297477. DOI: 10.1172/JCI106186. View

Hoffman T, Cestero R, Bullock W . Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med. 1970; 73(2):173-8. DOI: 10.7326/0003-4819-73-2-173. View

Stenson R, Constantino R, Harrison D . Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation. 1971; 43(2):205-11. DOI: 10.1161/01.cir.43.2.205. View

Whitsett T, Dayton P, MCNAY J . The effect of hepatic blood flow on the hepatic removal rate of oxyphenbutazone in the dog. J Pharmacol Exp Ther. 1971; 177(1):246-55. View

Acocella G, BONOLLO L, GARIMOLDI M, Mainardi M, TENCONI L, NICOLIS F . Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972; 13(1):47-53. PMC: 1411976. DOI: 10.1136/gut.13.1.47. View

Bieger R, de Jonge H, Loeliger E . Influence of nitrazepam on oral anticoagulation with phenprocoumon. Clin Pharmacol Ther. 1972; 13(3):361-5. DOI: 10.1002/cpt1972133361. View

Mawer G, MILLER N, Turnberg L . Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol. 1972; 44(3):549-60. PMC: 1665818. DOI: 10.1111/j.1476-5381.1972.tb07292.x. View

Weiner M, CHENKIN T, Burns J . Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. Am J Med Sci. 1954; 228(1):36-9. DOI: 10.1097/00000441-195407000-00004. View

10.

Conney A, Davison C, GASTEL R, Burns J . Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. J Pharmacol Exp Ther. 1960; 130:1-8. View

11.

Nelson E . RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION. Am J Med Sci. 1964; 248:657-9. DOI: 10.1097/00000441-196412000-00004. View

12.

Brodie B, Axelrod J . The fate of antipyrine in man. J Pharmacol Exp Ther. 1950; 98(1):97-104. View

13.

Kunin C, GLAZKO A, FINLAND M . Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest. 1959; 38:1498-508. PMC: 293281. DOI: 10.1172/JCI103928. View

14.

Brodie B, Burns J, Weiner M . Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med. 1959; 1:290-2. DOI: 10.1159/000134806. View